Clinical Trials Browser

Active not recruiting × Pathologic Complete Response × Clear all

Pathologic Complete Response, Breast Neoplasms

NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Phase EARLY_PHASE1 Active not recruiting

17 enrolled

Pathologic Complete Response

NCT01844986 2025-12-10

SOLO-1

Phase 3 Active not recruiting

450 enrolled 18 charts 1 FDA

Gynecologic

Pathologic Complete Response, Ovarian Neoplasms

NCT04229979 2025-10-01

REGAL

Phase 3 Active not recruiting

127 enrolled

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

325 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06087718 2025-08-14

Feasibility of the Maastro Applicator in Rectal Cancer

Phase NA Active not recruiting

10 enrolled

Gastrointestinal

Pathologic Complete Response, Radiation Injuries, Rectal Neoplasms

NCT03522246 2025-06-24

ATHENA

Phase 3 Active not recruiting

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT01686334 2024-03-12

WIDEA

Phase 2 Active not recruiting

130 enrolled

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Clinical Trials

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

SOLO-1

REGAL

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Feasibility of the Maastro Applicator in Rectal Cancer

ATHENA

WIDEA